Norbert Nass^1,2,#, Mohamad-Kamal Yaakoub^1,#, Alexandra-Victorita Simion³, Hartmut Kroll⁴, Sabine Westphal³, Judith Pannier¹, Gerhard Behre^1,*

Oncology Research, Vol.33, No.10, pp. 2923-2935, 2025, DOI:10.32604/or.2025.067561 - 26 September 2025

Abstract Background: Patients with hemato-oncological malignancies may respond insufficiently to vaccination, especially in terms of antibody titer. The antibody response depends on the type of malignancy as well as the type and timing of treatment. We intended to evaluate this using real-world data from patients of our regional hospital. This study also considers the role of immune status, including T-cell activation markers, in predicting vaccination success. Methods: Seventeen patients of our hospital having a hematological malignancy were included in this study, including myeloma, lymphoma, as well as acute myeloid leukemia (AML) and chronic lymphoid leukemia (CLL).… More >

CHIOMA C. EZEUKO^#, SANDANI V. T. WIJERATHNE^#, QIANA L. MATTHEWS^*

BIOCELL, Vol.49, No.9, pp. 1605-1629, 2025, DOI:10.32604/biocell.2025.065474 - 25 September 2025

Abstract Extracellular vesicles (EVs) have arisen as potential therapeutic tools in managing infectious diseases because EVs can regulate cell-to-cell signaling, function as drug transport mechanisms, and influence immune reactions. They are obtained from a myriad of sources, such as plants, humans, and animal cells. EVs like exosomes and ectosomes can be utilized in their native form as therapeutics or engineered to encompass antimicrobials, vaccines, and oligonucleotides of interest with a targeted delivery strategy. An in-depth understanding of host-pathogen dynamics provides a solid foundation for exploiting its full potential in therapeutics against infectious diseases. This review mainly More >

Raffaele Carrano^1,#, Carlotta Zucca^1,#, Nicla Cristina¹, Martina Grande¹, Eleonora Leti Maggio¹, Riccardo Bei², Antonio Infante², Chiara Focaccetti¹, Valeria Lucarini³, Loredana Cifaldi¹, Laura Masuelli⁴, Luciano Mutti⁵, Camilla Palumbo¹, Monica Benvenuto¹, Roberto Bei^1,*

Oncology Research, Vol.33, No.9, pp. 2181-2204, 2025, DOI:10.32604/or.2025.066708 - 28 August 2025

Abstract Mesothelioma is a rare and aggressive cancer with a poor prognosis and limited therapeutic options. Despite recent advances, conventional treatment approaches remain largely ineffective due to late diagnosis, chemoresistance and immunosuppressive tumor microenvironment. This review reports the latest studies on combination therapies for mesothelioma, focusing on the potential of integrating chemotherapeutic agents, molecularly targeted agents, vaccines and natural bioactive compounds such as polyphenols. Clinical and preclinical studies demonstrate that integrating immune-modulating drugs or molecular inhibitors with chemotherapy can improve survival and reduce tumor progression in mesothelioma models and patients. Vaccine-based strategies show potential for inducing More > Graphic Abstract

Wenfei Luo^1,#, Dingming Song^2,#, Yibo He³, Judong Song^4,*, Yunzhen Ding^5,*

Oncology Research, Vol.33, No.8, pp. 1875-1893, 2025, DOI:10.32604/or.2025.063843 - 18 July 2025

Abstract Malignant melanoma, characterized by its high metastatic potential and resistance to conventional therapies, presents a major challenge in oncology. This review explores the current status and advancements in tumor vaccines for melanoma, focusing on peptide, DNA/RNA, dendritic cell, tumor cell, and neoantigen-based vaccines. Despite promising results, significant challenges remain, including the immunosuppressive tumor microenvironment, patient heterogeneity, and the need for more effective antigen presentation. Recent strategies, such as combining vaccines with immune checkpoint inhibitors (ICIs), aim to counteract immune evasion and enhance T cell responses. Emerging approaches, including personalized neoantigen vaccines and the use of More > Graphic Abstract

Xiaobing Li^1,2, Yongsheng Liu¹, Limin Wei¹, Li Rao¹, Jingxin Mao^1,*, Xuemei Li^3,*

BIOCELL, Vol.49, No.5, pp. 813-832, 2025, DOI:10.32604/biocell.2025.062124 - 27 May 2025

Abstract Yeast-based models have become a powerful platform in pharmaceutical research, offering significant potential for producing complex drugs, vaccines, and therapeutic agents. While many current drugs were discovered before fully understanding their molecular mechanisms, yeast systems now provide valuable insights for drug discovery and personalized medicine. Recent advancements in genetic engineering, metabolic engineering, and synthetic biology have improved the efficiency and scalability of yeast-based production systems, enabling more sustainable and cost-effective manufacturing processes. This paper reviews the latest developments in yeast-based technologies, focusing on their use as model organisms to study disease mechanisms, identify drug targets,… More >

MARTA SANTOS¹, DIANA MARTINS^1,2,3,4, FERNANDO MENDES^1,2,3,4,5,*

Oncology Research, Vol.33, No.2, pp. 263-281, 2025, DOI:10.32604/or.2024.052207 - 16 January 2025

Abstract Background: Gastric Cancer (GC) is the 5th most prevalent and 4th most deadly neoplasm globally. Immunotherapy has emerged as a promising treatment approach in GC, potentially improving positive clinical outcomes while addressing the limitations of conventional therapies. GC immunotherapy modalities consist of adoptive cell therapy (ACT), cancer vaccines, and immune checkpoint inhibitors (ICI). Objectives: This systematic review aims to provide an overview of the advances in immune-based therapeutic approaches in GC, highlighting the potential of this therapy as a strategy for GC treatment. Methods: Key studies investigating several immunotherapeutic agents and combination therapies were searched in… More > Graphic Abstract

SHUBHRA CHANDRA^1,2, JENNIFER C. WILSON^1,2, DAVID GOOD³, MING Q. WEI^1,2,*

Oncology Research, Vol.32, No.10, pp. 1543-1564, 2024, DOI:10.32604/or.2024.043987 - 18 September 2024

Abstract The advent of RNA therapy, particularly through the development of mRNA cancer vaccines, has ushered in a new era in the field of oncology. This article provides a concise overview of the key principles, recent advancements, and potential implications of mRNA cancer vaccines as a groundbreaking modality in cancer treatment. mRNA cancer vaccines represent a revolutionary approach to combatting cancer by leveraging the body’s innate immune system. These vaccines are designed to deliver specific mRNA sequences encoding cancer-associated antigens, prompting the immune system to recognize and mount a targeted response against malignant cells. This personalized… More > Graphic Abstract

Andrew Omame^1,2,*, Mujahid Abbas^3,6, Dumitru Baleanu^4,5,6

CMES-Computer Modeling in Engineering & Sciences, Vol.138, No.3, pp. 2973-3012, 2024, DOI:10.32604/cmes.2023.029681 - 15 December 2023

Abstract A patient co-infected with COVID-19 and viral hepatitis B can be at more risk of severe complications than the one infected with a single infection. This study develops a comprehensive stochastic model to assess the epidemiological impact of vaccine booster doses on the co-dynamics of viral hepatitis B and COVID-19. The model is fitted to real COVID-19 data from Pakistan. The proposed model incorporates logistic growth and saturated incidence functions. Rigorous analyses using the tools of stochastic calculus, are performed to study appropriate conditions for the existence of unique global solutions, stationary distribution in the More >

PRIYADHARSHINI THANJAVUR SRIRAMAMOORTHI^1,2, GAYATHRI GOPAL^1,2, SHIBI MURALIDAR^1,2, SAI RAMANAN ESWARAN^1,2, DANUSH NARAYAN PANNEERSELVAM^1,2, BHUVANESWARAN MEIYANATHAN^1,2, SRICHANDRASEKAR THUTHIKKADU INDHUPRAKASH^1,2, SENTHIL VISAGA AMBI^1,2,*

BIOCELL, Vol.47, No.11, pp. 2335-2350, 2023, DOI:10.32604/biocell.2023.029379 - 27 November 2023

Abstract The novel coronavirus pneumonia (COVID-19) is spreading worldwide and threatening people greatly. The routes by which SARS-CoV-2 causes lung injury have grown to be a major concern in the scientific community since patients with new Coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV-2) have a high likelihood of developing acute respiratory distress syndrome (ARDS) in severe cases. The mortality rate of COVID-19 has increased over the period due to rapid spread, and it becomes crucial to understand the disease epidemiology, pathogenic mechanisms, and suitable treatment strategies. ARDS is a respiratory disorder and is one of the… More > Graphic Abstract

HANYANG GUAN^1,#, YUE WU^2,#, LU LI^3,#, YABING YANG¹, SHENGHUI QIU¹, ZHAN ZHAO¹, XIAODONG CHU¹, JIASHUAI HE¹, ZUYANG CHEN¹, YIRAN ZHANG¹, HUI DING¹, JINGHUA PAN^1,*, YUNLONG PAN^1,*

Oncology Research, Vol.31, No.4, pp. 437-448, 2023, DOI:10.32604/or.2023.029924 - 25 June 2023

Abstract Neoantigen-targeted immunotherapy is a rapidly advancing field that holds great promise for treating cancer. The recognition of antigens by immune cells is a crucial step in tumor-specific killing, and neoantigens generated by mutations in cancer cells possess high immunogenicity and are selectively expressed in tumor cells, making them an attractive therapeutic target. Currently, neoantigens find utility in various domains, primarily in the realm of neoantigen vaccines such as DC vaccines, nucleic acid vaccines, and synthetic long peptide vaccines. Additionally, they hold promise in adoptive cell therapy, encompassing tumor-infiltrating cells, T cell receptors, and chimeric antigen More > Graphic Abstract